- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
DCGI says WHO drew premature link between children deaths in Gambia, Maiden Pharma Cough Syrups
Overview
Calling out the World Health Organisation (WHO) for "prematurely" blaming an Indian company for the deaths without verification, India's drug regulator claimed that the samples of Maiden Pharma's cough syrups suspected of being linked to deaths of children in Gambia were not contaminated glycol (DEG) and ethylene glycol (EG), and have been found to be of standard quality.
In wake of this confirmation given by the Drug Controller General of Indian (DCGI), Maiden Pharmaceuticals Ltd on Friday said that it will seek clearance to re-open its factory as the Indian government laboratory found nothing wrong in samples taken from syrups namely Promethazine Oral Solution BP, KOFEXMALIN Baby Cough Syrup, MaKOFF Baby Cough syrup and MaGrip n Cold Syrup.
For more details, check out the link given below:
DCGI Calls Out WHO For 'Prematurely' Blaming Maiden Pharma For Cough Syrup Linked Deaths In Gambia